目次

Table of Content

1. Introduction to Natural Killer (NK) Cell Therapy

2. Mechanism Of Action of NK Cell Therapy
2.1 Cytotoxic Action Of NK Cells
2.2 Working Of NK Cell Therapy
2.3 NK Cell Therapies Approaches
2.3.1 CAR NK Cell Therapies
2.3.2 TCR NK Cell Therapies

3. Treatment Strategies For NK Cell Therapies
3.1 NK Cell Therapy As Monotherapy
3.2 NK Cell Therapy As Combinatorial Agent

4. Natural Killer (NK) Cell Therapy Research and Development Trends By Indication
4.1 Cancer
4.1.1 Hematological Cancers
4.1.2 Solid Cancers
4.2 Autoimmune and Inflammatory Disorders
4.3 Microbial Infections
4.4 Neurodegenerative Diseases

5. NK Cell Therapy Characteristics Enhancement Approaches
5.1 Use Of Nanotechnology
5.2 Modifications In CARs
5.3 Use Of CRISPR/Cas9 Gene Editing

6. Global Natural Killer Cell Therapies Clinical Trials Overview
6.1 By Country
6.2 By Indication
6.3 By Patient Segment
6.4 By Phase
6.5 By Priority Status

7. Global Natural Killer Cell Therapies Clinical Trials By Company, Indication and Phase
7.1 Research
7.2 Preclinical
7.3 Phase-0
7.4 Phase-I
7.5 Phase-I/II
7.6 Phase-II
7.7 Phase-II/III

8. NK Cell Based Therapy Proprietary Approaches and Technologies Insight
8.1 Overview
8.2 Proprietary Technologies By Company

9. Partnerships and Funding for NK Cell Therapies
9.1 Recent Partnerships, Collaborations and Licensing Agreements
9.2 Funding Deals By Companies

10. Investigational NK Cell Therapies With FDA Designations
10.1 FDA Fast Track Designation
10.2 FDA Orphan Drug Designation
10.3 Regenerative Medicine Advanced Therapy Designation

11. NK Cell Therapies Market Trends and Clinical Trials Outlook
11.1 Current Market Trends, Developments and Clinical Trials Assessment
11.2 Future Commercialization Opportunity

12. Competitive Landscape
12.1 Acepodia
12.2 Beijing JD Biotech
12.3 Cartherics
12.4 Catamaran Bio
12.5 Century Therapeutics
12.6 City of Hope National Medical Center
12.7 CRISPR Therapeutics
12.8 CytoImmune Therapeutics
12.9 Cytovia Therapeutics
12.10 Dragonfly Therapeutics
12.11 Editas Medicine
12.12 Fate Therapeutics
12.13 Gamida-Cell
12.14 GC Biopharma/GC Lab Cell
12.15 GICELL
12.16 Glycostem
12.17 HK inno.N
12.18 ImmunityBio
12.19 Karolinska Institute
12.20 Kiadis Pharma
12.21 Nkarta Therapeutics
12.22 NKGen Biotech
12.23 ONK Therapeutics
12.24 Sanofi
12.25 Senti Biosciences
12.26 Shoreline Biosciences
12.27 Sian Wuhan Medical Technology
12.28 Smart Immune
12.29 Sorrento Therapeutics
12.30 Therabest Korea
12.31 University of Texas M. D. Anderson Cancer Center
12.32 XNK Therapeutics
12.33 Zelluna Immunotherapy

List of Figures
Figure 1-1: NK Cells - Identification and Discovery Timeline
Figure 1-2: NK Cell Subsets - CD56low/dim v/s CD56bright
Figure 2-1: Cytotoxic Action Of NK Cells
Figure 2-2: CAR-NK Cells Preparation
Figure 2-3: Delivery Of CAR Gene Into NK Cell
Figure 2-4: NK Cells Sources For Therapy
Figure 2-5: Structure Of CAR/TCR-NK Cell
Figure 4-1: PRAME-TCR-NK Cells Therapy Phase 1/2 (NCT06383572) Study - Initiation and Completion Year
Figure 4-2: GCC2005A-P101 Phase 1 (NCT06699771) Study - Initiation and Completion Year
Figure 4-3: QUILT-106 Phase 1 (NCT06334991) Study - Initiation and Completion Year
Figure 4-4: TAK-007-2001 Phase 2 (NCT05020015) Study - Initiation and Completion Year
Figure 4-5: Indapta-Trial-1 Phase 1/2 (NCT06119685) Study - Initiation and Completion Year
Figure 4-6: PRAMETIME-Mel Phase 1 (NCT06660420) Study - Initiation and Completion Year
Figure 4-7: Ntrust-1 Phase 1 (NCT06557265) Study - Initiation and Completion Year
Figure 4-8: Ntrust-2 Phase 1 (NCT06733935) Study - Initiation and Completion Year
Figure 4-9: IDP023-2-101 Phase 1 (NCT06677710) Study - Initiation and Completion Year
Figure 4-10: CALiPSO-1 Phase 1 (NCT06255028) Study - Initiation and Completion Year
Figure 5-1: Improvements In NK Cell Therapy Using Nanotechnology
Figure 5-2: Basic Structure Of CARs On NK Cell
Figure 5-3: Gene Editing Tools
Figure 6-1: Global - NK Cell Therapies Clinical Trials By Country, 2025
Figure 6-2: Global - NK Cell Therapies Clinical Trials By Indication, 2025
Figure 6-3: Global - NK Cell Therapies Clinical Trials By Patient Segment, 2025
Figure 6-4: Global - NK Cell Therapies Clinical Trials By Phase, 2025
Figure 6-5: Global - NK Cell Therapies Clinical Trials By Priority Status, 2025
Figure 8-1: Artiva Biotherapeutics - Proprietary CAR-NK Cell Platform
Figure 8-2: Artiva Biotherapeutics - Proprietary AlloNKTM NK Cell Therapy Scaling Platform
Figure 8-3: Catamaran Bio - Proprietary Tailwindandreg; Platform
Figure 8-4: Cellularity - CYNK-CARs
Figure 8-5: GAIA BioMedicine - Proprietary NK Cell Therapy Working Mechanism
Figure 8-6: GAIA BioMedicine - Proprietary Technologies’ Salient Features
Figure 8-7: Gamida Cell - NK Cell Therapy Manufacturing Process
Figure 8-8: HebeCell - Proprietary Scalable NK Cell Technology
Figure 8-9: ImmunityBio - Proprietary haNKandreg; Cell Structure
Figure 8-10: Nkarta - Proprietary CAR-NK Cell Structure
Figure 8-11: Nkarta - Proprietary NK Cell Therapy Platform
Figure 8-12: Senti Biosciences - Gene Circuit Technology Platform
Figure 8-13: Senti Biosciences - Gene Circuit Technology Platform Applicability
Figure 8-14: Wugen - Proprietary Memory NK Cell Platform

List Of Tables
Table 10-1: Investigational NK Cell Therapies With Fast Track Designation
Table 10-2: Investigational NK Cell Therapies With Orphan Drug Designation
Table 10-3: Investigational NK Cell Therapies With Regenerative Medicine Advanced Therapy Designation